Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing.

ABSTRACT:

Introduction

Insulin icodec is a novel, long-acting insulin analog designed to cover basal insulin requirements with once-weekly subcutaneous administration. Here we describe the molecular engineering and the biological and pharmacological properties of insulin icodec.

Research design and methods

A number of in vitro assays measuring receptor binding, intracellular signaling as well as cellular metabolic and mitogenic responses were used to characterize the biological properties of insulin icodec. To evaluate the pharmacological properties of insulin icodec in individuals with type 2 diabetes, a randomized, double-blind, double-dummy, active-controlled, multiple-dose, dose escalation trial was conducted.

Results

The long half-life of insulin icodec was achieved by int

SUBMITTER: Nishimura E 

PROVIDER: S-EPMC8378355 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature